Cancer Risk and Prevention

Multiple Endocrine Neoplasia Type 1 (MEN1)

People with multiple endocrine neoplasia type 1 (MEN1) have a higher risk of some cancers and other tumors of the endocrine system.

What is multiple endocrine neoplasia type 1 (MEN1)?

MEN1 is a hereditary condition that increases the risk of developing certain cancers and other tumors.

MEN1 is rare. It affects approximately 1 in 50,000 people and can affect both males and females.

Most often, people with this condition develop tumors in certain glands of the endocrine system, but it can affect other parts of the body as well. The endocrine system makes hormones, which help manage body functions like temperature, how bodies grow and develop, and the levels of certain substances in the body such as blood sugar and calcium.

The most common tumors in MEN1 involve the:

  • Pituitary gland
  • Parathyroid gland
  • Pancreas or intestines

What causes multiple endocrine neoplasia type 1 (MEN1)?

MEN1 is caused by certain gene changes (mutations) in the MEN1 gene. MEN1 can occur when:

  • A gene change is inherited from one parent, or
  • A normal gene copy changes before a person is born, causing the gene change to be in cells throughout the body

The MEN1 gene normally works as a tumor suppressor gene. This gene makes sure that only healthy cells continue to grow and divide when needed. When a gene change occurs on the MEN1 gene, it can stop it from working as it should. This can allow cells to grow out of control and tumors to form.

Learn more about Genes and Cancer.

Does multiple endocrine neoplasia type 1 (MEN1) increase a person’s cancer risk?

Yes, MEN1 can increase the risk of certain types of cancer. Many of the MEN1-related endocrine tumors are not cancer, but some tumors are. MEN1 increases the chance of developing the following tumors.

Most of these tumors are benign (not cancer).

Most pituitary tumors are benign (not cancer). However, they can cause problems because of the hormones they produce. Or they can grow and press on important structures, such as the brain and nerves of the eyes.

Some neuroendocrine tumors are more likely to be cancerous than others. For example, gastrinomas, glucagonomas, and VIPomas are more often cancer and can spread to other parts of the body and nearby lymph nodes. Insulinomas are almost always benign (not cancer).

These tumors are malignant (cancer), although some tumors behave more aggressively than others. For example, NETs of the thymus tend to grow quickly and be difficult to treat. NETs of the bronchus (part of the lung) tend to grow more slowly.

Most tumors of the adrenal gland are benign (not cancer). In some cases, they can be cancer called adrenocortical carcinoma. Cancer is more likely in larger MEN1-related adrenal tumors.

Increased risk of non-endocrine cancers

Some other non-endocrine types of cancer are also more likely in people with MEN1.

Meningiomas are tumors that grow on the layers of tissue that cover the brain (meninges). While these tumors most often are not cancerous, they can sometimes cause problems. They might need treatment because of their location near important parts of the brain.

Ependymomas are brain tumors that grow from the ependymal cells that line the fluid filled areas of the brain called the ventricles. They can be low-grade (slow-growing) or high-grade (fast-growing) tumors that might need treatment because of their location near important parts of the brain.

Women with MEN1 have an increased risk of developing breast cancer during their life. Breast cancer in people with MEN1 has been seen at younger ages than expected.

What are the signs and symptoms of multiple endocrine neoplasia type 1 (MEN1)?

The signs and symptoms of MEN1 depend on whether a person has developed tumors related to the condition.

MEN1-related endocrine tumors and their symptoms

Symptoms of MEN1-related tumors depend on their location and size. Symptoms also depend on if the tumors make hormones and which hormones they make.

Endocrine system tumors that are most common in people with MEN1 include:

  • Parathyroid tumors
  • Pituitary adenomas
  • Neuroendocrine tumors (NET) of the pancreas and gastrointestinal tract
  • Thymic, bronchopulmonary (lung), and gastric (stomach) neuroendocrine tumors
  • Adrenocortical tumors

Tumors on the parathyroid glands, located in the neck, are almost always benign (not cancer). But they can cause the glands to be overactive and raise calcium levels in the blood.

Symptoms might include increased thirst, peeing more often, constipation, kidney stones, or low bone density.

In many cases parathyroid tumors do not cause symptoms and are found after blood work done for another reason shows high calcium levels.

Symptoms related to pituitary tumors depend on their size and the type of hormones they make, or if they make hormones at all.

The pituitary is located at the base of the brain near the optic nerves (nerves of the eye). Because of this, symptoms of pituitary tumors can include vision changes, especially peripheral vision (causing tunnel vision), if they grow large enough.

One of the more common pituitary tumors in MEN1 is called a prolactinoma. Prolactinomas make prolactin, a hormone that mainly causes breast milk production. This tumor can cause women to make breast milk, even if they are not pregnant or breastfeeding. It may also interrupt menstrual cycles. In men it can cause sexual dysfunction.

Other types of pituitary tumors can make other hormones. These include growth hormones, reproductive hormones, and stress hormones. Each type of hormone may cause different symptoms or cause no symptoms at all.

In people with MEN1, about 1 in 3 pituitary tumors don’t make any kind of hormones.

Symptoms caused by tumors of the pancreas and gastrointestinal tract depend on whether they make hormones and which hormone they make.

The most common type of MEN1-related tumor of the gastrointestinal tract is called a gastrinoma. It usually starts in the part of the small intestine called the duodenum. These tumors make the hormone gastrin. Too much of this hormone can cause stomach ulcers and diarrhea, a condition called Zollinger-Ellison syndrome.

Other, less common, neuroendocrine tumors can develop in the pancreas, including:

  • Insulinomas, which make insulin and can cause low blood sugar levels
  • Glucagonomas, which make glucagon and can cause high blood sugar, anemia, and diarrhea
  • VIPomas, which make vasoactive intestinal peptide (VIP) and can cause severe diarrhea and low salts in the blood

Previously called carcinoid tumors, these neuroendocrine tumors can sometimes make hormones that cause symptoms like flushing of the face, diarrhea, wheezing, or palpitations. When this happens, it is called carcinoid syndrome.

Most of these tumors do not make hormones, though. These tumors might or might not cause symptoms, depending on their location and size.

Adrenocortical tumors start in the adrenal glands, which sit on top of each kidney. Some adrenocortical tumors can produce hormones that cause the body to make cortisol, a steroid that usually helps the body respond to stress. When too much cortisol is made, it can cause symptoms such as:

  • Weight gain
  • Stretch marks
  • High blood pressure
  • High blood sugar levels
  • Muscle weakness

Some of these tumors may not cause any symptoms.

MEN1-related non-endocrine tumors and their symptoms

People with MEN1 are also more likely to develop tumors outside of the endocrine glands, including:

  • Benign growths of the skin and fat such as angiofibromas, collagenomas, and lipomas, which can be seen or felt on the skin.
  • Breast cancer, which can be felt as a lump or skin change on the breast.
  • Certain brain tumors such as meningiomas and ependymomas, which can cause headaches, changes in balance, changes in speech, and affect hearing or vision.
  • Uterine leiomyomas (fibroids), which can cause heavy or irregular vaginal bleeding, abdominal pain, and feelings of fullness or abdominal discomfort.

How is multiple endocrine neoplasia type 1 (MEN1) diagnosed?

MEN1 can be diagnosed based on clinical criteria or genetic testing.

Clinical criteria for MEN1 includes having:

  • A personal history of 2 or more of the main MEN1-related tumors: parathyroid, pancreatic or GI neuroendocrine, or pituitary
  • A close family member diagnosed with MEN1 and a personal history of 1 of the main MEN1-related tumors: parathyroid, pancreatic or GI neuroendocrine, or pituitary

Genetic testing may be suggested even if you have no MEN1-related tumors. For example, your care team might suggest testing if you have a close family member with MEN1. It could also be recommended if you have:

  • An overactive parathyroid gland (hyperparathyroidism) before age 30
  • A pancreatic neuroendocrine tumor before the age of 40
  • A pituitary tumor that makes hormones, is larger than 1 centimeter (cm), or develops before age 19

Genetic testing can be done on a blood, saliva (spit) or a cheek (buccal) swab sample.

How is multiple endocrine neoplasia type 1 (MEN1) found, managed and treated?

MEN1 is found and managed with close follow-up and screening tests. Early screening tests may catch tumors before symptoms start, when treatment is more likely to be successful. There is no cure for MEN1.

Screening recommendations for people with MEN1

Regular tests and exams help manage the risk of MEN1-related tumors. Recommended tests for people with no symptoms might include:

  • Yearly history and physical exam with a healthcare provider familiar with MEN1, with close attention to growth and development in younger people and to possible symptoms of abnormal hormone levels in all people
  • Blood tests that check calcium levels starting around age 10, every 1 to 3 years until age 18, then yearly after that*
  • Blood tests that check fasting gastrin levels in people over age 18
  • Abdominal MRI starting between ages 10 to 15, then every 2 to 3 years if no tumor is found
  • Chest CT scan starting between ages 20 to 25, then every 3 to 5 years if no tumor is found
  • Pituitary MRI beginning between ages 15 and 19, then every 3 to 5 years if no tumor is found, until age 75

*Blood tests might also check for growth factor (IGF-1) and prolactin levels starting at age 10 to watch for pituitary tumors that make extra hormones.

Treatment of multiple endocrine neoplasia type 1 (MEN1)-related tumors

The treatment of MEN1 depends on the tumors that develop, whether they are cancerous, and whether they cause symptoms. These tumors are often treated the same way in people with MEN1 and people without MEN1.

If a high level of parathyroid hormone is causing symptoms, it might be treated with surgery to remove most of the parathyroid glands and possibly part of the thymus. If surgery is not an option, it might be treated with medicines to lower calcium levels. If parathyroid tumors do not cause symptoms, no treatment may be needed.

Treatment for pituitary tumors depends on whether they make hormones and their size. These tumors are treated the same as in people without MEN1.

For more information, see Treating Pituitary Tumors.

Treatment for these tumors depends on their size, if they are cancer, and whether they make hormones.

Small tumors that do not make hormones might just be watched. But larger tumors, tumors that are growing quickly, or tumors that make hormones are often removed with surgery.

Tumors that have spread might be treated with chemotherapy, targeted drugs, or other treatments like radiation or ablation, where treatments like heat, cold, or other substances are used to destroy tumors that cause problems.

Other medicines may be used to treat symptoms of extra hormones being made by these types of tumors. For example, medicines that lower stomach acid might be used in the case of a gastrinoma.

For more information, visit Treating Pancreatic Neuroendocrine Tumors or Treating Gastrointestinal Neuroendocrine Tumors.

Often the location, size, and how fast an NET grows is used to decide if a tumor might be watched with imaging or needs treatment right away.

In general, larger NETs and those that are growing quickly are more likely to need treatment. Thymic NETs might grow and spread quickly, so doctors often recommend treatment as soon as they are found. Surgery may be an option if the tumor can be completely removed. Cancer that is left behind may be treated with radiation or chemotherapy.

Smoking increases the risk of developing an NET, especially in the thymus. People with MEN1 should avoid smoking. Some men might be advised to have their thymus removed to reduce the risk of developing a thymus NET. This is especially true for men who smoke.

For more information, visit Treating Lung Neuroendocrine Tumors or Treating Gastrointestinal Neuroendocrine Tumors.

Most adrenocortical tumors in people with MEN1 are not cancer. However, tumors that make hormones, are large, or are suspicious for cancer (growing quickly) are usually removed with surgery.

For more information, see Treating Adrenal Cancer.

Breast cancer and brain tumors in people with MEN1 are treated the same way as in people without MEN1.

Questions to ask your healthcare team

If you or a family member has MEN1, consider asking your care team:

  • What is my risk of developing cancer or other tumors related to MEN1?
  • Does my family history increase my risk of cancer or other tumors? Should I get genetic testing?
  • What types of screening tests should I have? When should I have these tests?
  • What signs or symptoms should I watch for?
  • Are there things I can do to lower my risk of cancer or other tumors?

American Cancer Society logo

The American Cancer Society medical and editorial content team

Our team is made up of doctors and oncology certified nurses with deep knowledge of cancer care as well as editors and translators with extensive experience in medical writing.

Al-Salameh A, Cadiot G, Calender A, Goudet P, Chanson P. Clinical aspects of multiple endocrine neoplasia type 1. Nat Rev Endocrinol. 2021;17(4):207-224.

Arnold A, Newey P. Multiple Endocrine Neoplasia type 1: Clinical manifestations and diagnosis. UpToDate. 2026. Accessed at https://www.uptodate.com/contents/multiple-endocrine-neoplasia-type-1-clinical-manifestations-and-diagnosis on April 22, 2026.

Arnold A, Newey P. Multiple Endocrine Neoplasia type 1: Genetics. UpToDate. 2026. Accessed at https://www.uptodate.com/contents/multiple-endocrine-neoplasia-type-1-genetics on April 22, 2026.

Arnold A, Newey P. Multiple Endocrine Neoplasia type 1: Management. UpToDate. 2026. Accessed at https://www.uptodate.com/contents/multiple-endocrine-neoplasia-type-1-management on April 22, 2026.

Brandi ML, Pieterman CRC, English KA, et al. Multiple endocrine neoplasia type 1 (MEN1): recommendations and guidelines for best practice. Lancet Diabetes Endocrinol. 2025;13(8):699-721.

Del Rivero J, Gangi A, Annes JP, et al. American Association of Clinical Endocrinology Consensus Statement on Management of Multiple Endocrine Neoplasia Type 1. Endocr Pract. Published online March 26, 2025.

Giusti F, Marini F, Brandi ML. Multiple Endocrine Neoplasia Type 1. 2005 Aug 31 [Updated 2022 Mar 10]. In: Adam MP, Bick S, Mirzaa GM, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2026. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1538/

Thakker RV, Newey PJ, Walls GV, et al. Clinical practice guidelines for multiple endocrine neoplasia type 1 (MEN1). J Clin Endocrinol Metab. 2012;97(9):2990-3011.

Wasserman JD, Schneider KW, Achatz MI, et al. Updated Recommendations for Pediatric Surveillance in Hereditary Endocrine Neoplasia Syndromes: Multiple Endocrine Neoplasias, Hyperparathyroidism-Jaw Tumor Syndrome, and Carney Complex. Clin Cancer Res. 2025;31(17):3628-3637.

Last Revised: August 19, 2026

American Cancer Society Emails

Sign up to stay up-to-date with news, valuable information, and ways to get involved with the American Cancer Society.